Barclays analyst Geoff Meacham and team argue that sales of Gilead Sciences’ (GILD) hepatitis-C drugs could surprise to the upside: In 2016, Street forecasts for Gilead’s hepatitis C (hep C) franchise call for a ~20% y/y decline in US sales. Continue reading
The tumble in share prices for biotechnology stocks has created some buying opportunities, with drugmakers Celgene. Continue reading
Investment managers are warning that markets probably have further to fall as China’s growth slows, oil prices. Continue reading
When the stock market hands you lemons, make a lemonade-flavored pill. That is one option for drugmakers, who can. Continue reading
Which biotech stocks are buys in 2016? Alethia Young, the new biotech analyst at Credit Suisse, weighed in with. Continue reading
